Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study

This letter to the editor summarises a study used to assess the impact of erythropoiesis-stimulating agents (ESA) treatment on overall survival and on the evolution of MDS into acute myeloid leukaemia.

Download Article

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator

Click here

MDS Factsheet for GPs General Practicioners

Click here

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

Click here

This is an external link to the home of the British Society for Haematology (BSH). 

Click here